A Randomised, Double Blind, Double Dummy, Active Comparator and Placebo Controlled Confirmative Non-inferiority Trial of FP187 Compared to Fumaderm in Moderate to Severe Plaque Psoriasis

Trial Profile

A Randomised, Double Blind, Double Dummy, Active Comparator and Placebo Controlled Confirmative Non-inferiority Trial of FP187 Compared to Fumaderm in Moderate to Severe Plaque Psoriasis

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 10 Aug 2016

At a glance

  • Drugs Dimethyl fumarate (Primary) ; Calcium monoethyl fumarate/dimethyl fumarate/magnesium monoethyl fumarate/zinc monoethyl fumarate
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Sponsors Forward Pharma
  • Most Recent Events

    • 08 Aug 2016 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 02 Feb 2016 Planned initiation date changed from 1 Sep 2013 to 1 Jun 2016, according to ClinicalTrials.gov record.
    • 05 Mar 2015 Planned End Date changed from 1 Aug 2014 to 1 Jun 2017 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top